🇺🇸 FDA

Company profile · Sponsor

Marker

Marker Therapeutics

MRKR · NYSE pharma HOUSTON, TX, USA
Pipeline
13
Drugs
0
Patents
8

Quick answer

Marker (MRKR) is a pharma company. headquartered in HOUSTON, TX, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker MRKR
Exchange NYSE
Company type pharma
Headquarters HOUSTON, TX, USA
SEC CIK 0001094038

Pipeline (13)

Search pipeline →

  1. FRα peptide plus Adjuvant (GM-CSF)

    Marker

    Platinum Sensitive Ovarian Cancer

    phase 2 mab terminated

    1 trial

  2. Low dose FRα vaccine

    Marker

    Breast Cancer

    phase 2 mab completed

    1 trial

  3. MT-401

    Marker

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  4. TPIV200

    Marker

    Ovarian Cancer

    phase 2 mab completed

    1 trial

  5. HER-2/neu peptide vaccine

    Marker

    HER2-positive Breast Cancer

    phase 1 mab completed

    1 trial

  6. MT-401-OTS

    Marker

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule active

    1 trial

  7. MT-601

    Marker

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial

  8. MT-601 dose 200 million cells

    Marker

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

  9. Mail-in Urine Test for EDCs

    Marker

    Endocrine Disrupting Chemicals

    other completed

    1 trial

  10. Urinary EDC metabolite testing

    Marker

    Obesity &Amp;Amp;Amp; Overweight

    other active

    1 trial

  11. Urinary EDC metabolite testing

    Marker

    Environmental Exposure

    other active

    1 trial

  12. blood sampling

    Marker

    Colorectal Cancer Screening

    other completed

    1 trial

  13. blood sampling

    Marker

    Screening for Colon Cancer

    other active

    1 trial

Patents (8)

Search patents →

  1. US 12077601

    Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11885817

    Biomarkers and methods for detection of seizures and epilepsy

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11692030

    Biomarkers and methods for detection of seizures and epilepsy

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11598782

    Biomarkers and methods for detection of seizures and epilepsy

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11447500

    Thienopyridine derivatives and pharmaceutical composition comprising same

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11186873

    Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11078298

    Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11008622

    Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Marker?

Marker (MRKR) is a pharma company. headquartered in HOUSTON, TX, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Marker sponsor?

We track 13 ClinicalTrials.gov-linked programs for Marker, including FRα peptide plus Adjuvant (GM-CSF) and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Marker company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.